Gerace Elisabetta, Polenzani Lorenzo, Magnani Maurizio, Zianni Elisa, Stocca Gabriella, Gardoni Fabrizio, Pellegrini-Giampietro Domenico E, Corradetti Renato
Department of NEUROFARBA, University of Florence, Viale G. Pieraccini 6, 50139, Florence, Italy; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Angelini Pharma S.p,A, Rome, Italy.
Neuropharmacology. 2023 Feb 1;223:109307. doi: 10.1016/j.neuropharm.2022.109307. Epub 2022 Nov 2.
Chronic treatment with serotonin selective reuptake inhibitors or tryciclic antidepressant drugs in rodents has been shown to increase the expression of GluA1 and/or GluA2 AMPA receptor (AMPAR) subunits in several brain areas, including the hippocampus. These changes in AMPAR composition have been suggested to result in increased glutamatergic neurotransmission and possibly underlie enhanced hippocampal synaptic plasticity through the increased availability of calcium-permeable AMPARs, specifically at CA3/CA1 synapses. However, the possibility that chronic treatment with antidepressants actually results in strengthened glutamatergic neurotransmission in CA1 has poorly been investigated. Here, we studied whether chronic treatment with the multimodal antidepressant drug trazodone mimicked the effect of paroxetine on the expression of AMPAR subunits in male wistar rat hippocampus and whether these drugs produced a parallel facilitation of field excitatory postsynaptic potentials (fEPSP) responses evoked by activation of CA3/CA1 synapses in dorsal hippocampal slices. In addition, we investigated whether the quality of glutamatergic AMPARs involved in basal neurotransmission was changed by altered subunit expression, e.g. leading to appearance of calcium-permeable AMPARs. We found a significant increase in GluA2 subunit expression following treatment with trazodone or paroxetine for twenty-one days, but not after seven-days treatment. In contrast, we did not find any significant changes in fEPSP responses supporting either a facilitation of glutamatergic neurotransmission in basal conditions or the appearance of functional calcium-permeable AMPARs at CA3/CA1 pyramidal neuron synapses. Thus, neurochemically-detected increases in the expression of AMPAR subunits cannot directly be extrapolated in increased number of functioning receptors and/or facilitated basal neurotransmission.
在啮齿动物中,长期使用血清素选择性再摄取抑制剂或三环类抗抑郁药物已被证明可增加包括海马体在内的多个脑区中GluA1和/或GluA2α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(AMPAR)亚基的表达。有人认为,AMPAR组成的这些变化会导致谷氨酸能神经传递增加,并可能通过增加钙通透性AMPAR的可用性,特别是在CA3/CA1突触处,从而增强海马体突触可塑性。然而,抗抑郁药的长期治疗是否真的会导致CA1区谷氨酸能神经传递增强,这一点尚未得到充分研究。在这里,我们研究了多模式抗抑郁药物曲唑酮的长期治疗是否能模拟帕罗西汀对雄性Wistar大鼠海马体中AMPAR亚基表达的影响,以及这些药物是否能同时促进背侧海马体切片中CA3/CA1突触激活所诱发的场兴奋性突触后电位(fEPSP)反应。此外,我们还研究了基础神经传递中涉及的谷氨酸能AMPAR的质量是否会因亚基表达的改变而发生变化,例如是否会导致钙通透性AMPAR的出现。我们发现,用曲唑酮或帕罗西汀治疗21天后,GluA2亚基表达显著增加,但治疗7天后没有增加。相比之下,我们没有发现fEPSP反应有任何显著变化,这表明在基础条件下谷氨酸能神经传递没有增强,CA3/CA1锥体神经元突触处也没有出现功能性钙通透性AMPAR。因此,神经化学检测到的AMPAR亚基表达增加不能直接推断为功能性受体数量增加和/或基础神经传递增强。